HDAC9 and ovarian carcinoma: Co-inhibition of ARTDs and histone deacetylases (HDAC) with Olaparib and Suberoylanilide Hydroxamic Acid (SAHA) respectively is an example where a positive synergy was demonstrated using HR-proficient ovarian cancer cell lines against which Olaparib alone has minimal efficacy as a single agent34.